ClinicalTrials.gg
RecruitingNCT06920043Updated Nov 5, 2026

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

A Phase 2 interventional study of Efimosfermin and Placebo in Metabolic Dysfunction-Associated Steatohepatitis and Non-alcoholic Fatty Liver Disease, sponsored by GlaxoSmithKline. Recruiting at 30 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Planned enrollment
277th of 460
42 · median 56
Started
2025
with 15 others
Phase 2
192 of 547
15 open now
Primary completion
2028-07
later than 64 of 92 live
Registered
531st of 547
by date
Lead sponsor
8 of 547
GlaxoSmithKline

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 277th largest by planned enrollment of the 460 interventional ones that give a count, is one of 16 that started in 2025, is one of 192 in phase 2, reaches primary completion later than 64 of the 92 other live ones, and was the 531st registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

54 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

03

Conditions studied

  • Metabolic Dysfunction-Associated Steatohepatitis
  • Non-alcoholic Fatty Liver Disease

Keywords

  • Fibroblast growth factor
  • Stage 4 fibrosis
  • Compensated Cirrhosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and sign a written form (ICF)
  • Age 18 through 75 years at enrollment
  • History or presence of 2 or more of the 5 components of metabolic syndrome
  • Liver confirmation of MASH consistent with stage F4 fibrosis
  • Other inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Individuals with chronic liver disease from other causes, or any history or evidence of decompensated liver disease
  • History of type 1 diabetes
  • (ALT) or aspartate aminotransferase (AST) ≥5 × the (ULN)
  • Other exclusion criteria may apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Efimosfermin (Dose 1)

    Participants will receive efimosfermin (Dose 1) once every 4 weeks (Q4W).

    Drug: Efimosfermin

  • Experimental
    Efimosfermin (Dose 2)

    Participants will receive efimosfermin (Dose 2) Q4W.

    Drug: Efimosfermin

  • Placebo comparator
    Placebo

    Participants will receive placebo Q4W.

    Drug: Placebo

Interventions

  • DrugEfimosfermin

    Efimosfermin will be administered as a subcutaneous injection.

    Also known as: BOS-580

  • DrugPlacebo

    Placebo will be administered as a subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment emergent adverse events (TEAEs)

    To assess the effects of efimosfermin on safety and tolerability.

    Time frame: From Day 1 to 100 weeks

Secondary outcomes

  1. Serum concentrations of efimosfermin

    To assess the steady-state PK of efimosfermin.

    Time frame: Up to Week 21

  2. Maximum serum drug concentration (Cmax) of efimosfermin

    To assess the steady-state PK of efimosfermin.

    Time frame: Up to Week 21

  3. Area under the serum concentration-time curve (AUC) of efimosfermin

    To assess the steady-state PK of efimosfermin.

    Time frame: Up to Week 21

  4. Average serum drug concentration (Cavg) of efimosfermin

    To assess the steady-state PK of efimosfermin.

    Time frame: Up to Week 21

  5. Concentration of study drug at the end of the dosing interval (Ctrough) of efimosfermin

    To assess the steady-state PK of efimosfermin.

    Time frame: Up to Week 21

07

Study locations

30 of 30 sites recruiting
  • GSK Investigational Site
    Chandler, Arizona 85224-4711, United States
    Recruiting
  • GSK Investigational Site
    Mesa, Arizona 85381, United States
    Recruiting
  • GSK Investigational Site
    Tucson, Arizona 85712, United States
    Recruiting
  • GSK Investigational Site
    Fresno, California 93720, United States
    Recruiting
  • GSK Investigational Site
    Lancaster, California 93534, United States
    Recruiting
  • GSK Investigational Site
    Pasadena, California 91105, United States
    Recruiting
  • GSK Investigational Site
    Rialto, California 92377, United States
    Recruiting
  • GSK Investigational Site
    Santa Maria, California 93458, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33156-7397, United States
    Recruiting
  • GSK Investigational Site
    Viera, Florida 32940, United States
    Recruiting
  • GSK Investigational Site
    Marietta, Georgia 30060-8948, United States
    Recruiting
  • GSK Investigational Site
    Baltimore, Maryland 21202, United States
    Recruiting
  • GSK Investigational Site
    Kansas City, Missouri 64131, United States
    Recruiting
  • GSK Investigational Site
    New York, New York 10029, United States
    Recruiting
  • GSK Investigational Site
    Fayetteville, North Carolina 28304, United States
    Recruiting
  • GSK Investigational Site
    Wilson, North Carolina 27612, United States
    Recruiting
  • GSK Investigational Site
    Austin, Texas 78745-5675, United States
    Recruiting
  • GSK Investigational Site
    Austin, Texas 78757-8066, United States
    Recruiting
  • GSK Investigational Site
    Austin, Texas 78757, United States
    Recruiting
  • GSK Investigational Site
    Dallas, Texas 75203, United States
    Recruiting
  • GSK Investigational Site
    Georgetown, Texas 78626, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77030, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77030, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77079, United States
    Recruiting
  • GSK Investigational Site
    Pasadena, Texas 77505, United States
    Recruiting
  • GSK Investigational Site
    Pearland, Texas 77584, United States
    Recruiting
  • GSK Investigational Site
    San Antonio, Texas 78215, United States
    Recruiting
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
    Recruiting
  • GSK Investigational Site
    Waco, Texas 76710, United States
    Recruiting
  • GSK Investigational Site
    Richmond, Virginia 23249-0001, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jul 2028, 38 months after the start.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's planned 38 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 9, 2025
StartActual
Apr 9, 2025
Primary completionEst.
Jul 3, 2028
CompletionEst.
Jul 3, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 10, 2028→Jul 3, 2028
Nov 5, 2026
Study completion
Jul 10, 2028→Jul 3, 2028
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Jul 10, 2028→Jul 3, 2028
    Study completion Jul 10, 2028→Jul 3, 2028
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06920043
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 9, 2025
Start date
Apr 9, 2025
Primary completion
Jul 3, 2028 (estimated)
Completion
Jul 3, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion